Long-term performance of single-connector (DF4) implantable defibrillator leads.

Aims: Single-connector (DF4) defibrillator leads have become the predominantly implanted transvenous implantable cardioverter-defibrillator lead. However, data on their long-term performance are derived predominantly from manufacturer product performance reports.
Methods and Results: We reviewed medical records in 5289 patients with DF4 leads between 2011 and 2023 to determine the frequency of lead-related abnormalities. We defined malfunction as any single or combination of electrical abnormalities requiring revision including a sudden increase (≥2×) in stimulation threshold, a discrete jump in high-voltage impedance, or sensing of non-physiologic intervals or noise. We documented time to failure, predictors of failure, and management strategies. Mean follow-up after implant was 4.15 ± 3.6 years (median = 3.63), with 37% of leads followed for >5 years. A total of 80 (1.5%) leads demonstrated electrical abnormalities requiring revision with an average time to failure of 4 ± 2.8 years (median = 3.5). Of the leads that malfunctioned, 62/80 (78%) were extracted and replaced with a new lead and in the other 18 cases, malfunctioned DF4 leads were abandoned, and a new lead implanted. In multivariable models, younger age at implant (OR 1.03 per year; P < 0.001) and the presence of Abbott/St. Jude leads increased the risk of malfunction.
Conclusion: DF4 defibrillator leads demonstrate excellent longevity with >98.3% of leads followed for at least 5 years still functioning normally. Younger age at implant and lead manufacturer are associated with an increased risk of DF4 lead malfunction. The differences in lead survival between manufacturers require further investigation.
Competing Interests: Conflict of interest:  A.d.S.: honoraria/speaking/consulting fee—Baylis Medical Company. M.S.L.: honoraria/speaking/consulting fee—Medtronic; Boston Scientific. D.B.D.L.: honoraria/speaking/consulting fee—Boston Scientific; Medtronic; AtriCure, Inc. A.M.P.: honoraria/speaking/consulting fee—Biosense Webster, Inc. M.F.E.-C.: honoraria/speaking/consulting fee—Boston Scientific; Medtronic. The rest of the authors have no disclosures
(© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)